IN8BIO, Inc. INAB
IN8BIO, Inc. (Nasdaq: INAB) is an immunology/inflammation drug developer. Its lead program, INB-619, is in Pre-clinical for B cell-driven autoimmune diseases (systemic lupus erythematosus). Its next catalyst on record is INB-200/INB-400: Additional mOS data at Society for Neuro-Oncology Annual Meeting (November 2026).
Upcoming catalysts
- November 2026INB-200/INB-400 — Additional mOS data at Society for Neuro-Oncology Annual Meeting
We expect to provide further clinical updates, including additional mOS data from the total data set, in an oral session at the Society for Neuro-Oncology Annual Meeting in November 2026.
- December 2026INB-100 — Clinical update at ASH Annual Meeting
We expect to complete the treatment of all patients and present a clinical update at the American Society of Hematology (ASH) Annual Meeting in December 2026.
Next further out: INB-619 — Initial in vivo data (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| INB-400 | Newly diagnosed glioblastoma | cell therapy | Phase 2 |
| INB-100 | High-risk leukemias undergoing haploidentical stem cell transplantation | cell therapy | Phase 1 |
| INB-200 | Newly diagnosed glioblastoma | cell therapy | Phase 1 |
| INB-619 | B cell-driven autoimmune diseases (systemic lupus erythematosus) | protein/peptide | Pre-clinical |
| INB-300 | Solid and liquid tumors | cell therapy | Pre-clinical |
| INB-500 | Various (iPSC-derived gamma-delta T cells) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.